GlassScriptPhysician profile
Heidi C Piper
NPI 1558364430
$4,414.94
in general payments reported to CMS, 2019-2025
18 companies · $611 in 2025
The $611 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $20.04 · 2021: $111 · 2022: $2,177 · 2023: $738 · 2024: $479 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,760.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $739.90 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $616.04 | 2019-2024 | Vabysmo |
| Abbvie INC. | $218.84 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $216.70 | 2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Horizon Therapeutics Plc | $210.70 | 2022-2023 | Tepezza |
| Eyepoint US, INC. | $125.17 | 2022-2023 | |
| Hoffmann-La Roche Limited | $125.00 | 2019 | |
| Astellas Pharma US INC | $117.89 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $88.13 | 2023-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Amgen INC. | $36.05 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.38 | 2019 | |
| Alimera Sciences, INC. | $29.98 | 2023 | Iluvien |
| Coherus Oncology, INC. | $24.33 | 2023 | |
| Spark Therapeutics, INC. | $20.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.88 | 2019 | |
| Alcon Vision LLC | $19.13 | 2024 | Rocklatan |
| Mallinckrodt Enterprises LLC | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Piper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.